



## SHORT CURRICULUM VITAE

**Panagiotis Skendros, MD, PhD**

**Professor of Internal Medicine**

April 2024

---

**First Name:** Panagiotis  
**Last Name:** Skendros  
**Year of birth:** 1971 (Greece)  
**Professional address:** First Department of Internal Medicine,  
University Hospital of Alexandroupolis,  
Democritus University of Thrace (DUTH), Greece  
**Contact details:** e-mail: [pskendro@med.duth.gr](mailto:pskendro@med.duth.gr)  
web: <https://www.inflathrace.gr/omades/panagiotis-skendros/>  
LinkedIn: <https://www.linkedin.com/in/panagiotis-skendros-ba3770155/>

Dr. Skendros is Professor of Internal Medicine at the First Department of Internal Medicine of University Hospital of Alexandroupolis, Democritus University of Thrace (DUTH), in Alexandroupolis. He is an active member of the faculty in the Department of Medicine since 2009. Dr. Skendros graduated from the Medical School of the Aristotle University of Thessaloniki (1995) and trained in Internal Medicine at the Infectious Diseases Hospital and Hippokration Hospital in Thessaloniki. He received his PhD in Immunology at the Aristotle University of Thessaloniki (2006). He received advanced training in Immunology at the Laboratoire Central d'Immunologie Cellulaire et Tissulaire of Pitie-Salpetriere Hospital, and at the INSERM/UPMC UMRS 945, Lab Immunogénétique, in Paris. His research interests focus on the fields of Immunology and Translational Medicine. In particular, his research group studies the role of neutrophils & NETosis in the regulation of inflammation and thrombosis in various clinical models of autoinflammation and infection. He is PI & Coordinator for EU and nationally funded programs (since 2018 ~1,800,000€). He has served as external reviewer in the evaluation of competitive research grants proposals for international organizations, such as the French National Research Agency (ANR), Worldwide Cancer Research (WCR), Dotan Center for Research in Hemato-Oncology, Portuguese Foundation for Science & Technology. He is a member of the Advisory Board and the Education & Training Committee of the European Society for Translational Medicine (EUSTM). He is a member of the European Federation of Internal Medicine (EFIM), and Director (2025-2027) of the European Summer School of Internal Medicine (ESIM) of EFIM. He was a member of the Board of Directors of the Hellenic Society of Immunology (2007-2010, 2019-2020). In parallel, he works as consultant at the University Hospital of Alexandroupolis with special interest for patients with systemic autoinflammatory and autoimmune diseases. Dr. Skendros is currently listed in the World Ranking of Top 2% Scientists in the 2023 updated database, made at the Stanford University,

<https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/6>

**Teaching:** Tutor in the training program of medical students of the Medical Department of DUTH. Lessons: Pathophysiology (Coordinator, 3<sup>rd</sup> year students), Physical Examination (3<sup>rd</sup> year students), Internal Medicine (4<sup>th</sup> and 6<sup>th</sup> year students), Principles of Clinical Immunology (5<sup>th</sup> year of studies). During daily clinical activities, trainer of resident internists as well as sixth year medical students in Internal Medicine and Therapeutics.

**Publications ([PubMed Link](#)):** Cumulative Impact Factor 604, Mean Impact Factor 8,5, Citations >5000, h-index 27 (Scopus).

### **Selected publications (PubMed), as main author in original research papers only**

- Gavriilidis E, Divolis G, Natsi Natsi AM, ....., **Skendros P**. Neutrophil-fibroblast crosstalk drives immunofibrosis in Crohn's disease through IFN $\alpha$  pathway. *medRxiv* 2023.09.08.23295281; doi: <https://doi.org/10.1101/2023.09.08.23295281>
- Chrysanthopoulou A, Antoniadou C, Natsi AM, ....., **Skendros P\***, Ritis K\*. Down-regulation of KLF2 in lung fibroblasts is linked with COVID-19 immunofibrosis and restored by combined inhibition of NETs, JAK-1/2 and IL-6 signaling. *Clin Immunol.* 2023 Feb;247:109240. \*co-supervision
- **Skendros P**, Germanidis G, Mastellos DC, et al. Complement C3 inhibition in severe COVID-19 using compstatin AMY-101. *Sci Adv.* 2022 Aug 19;8(33):eabo2341.
- Mitroulis I, Chrysanthopoulou A, Divolis G,....., **Skendros P**. A gene expression map of host immune response in human brucellosis. *Front Immunol.* 2022 Aug 1;13:951232. doi: 10.3389/fimmu.2022.951232.
- Chrysanthopoulou A, Gkaliagkousi E, Lazaridis A,....., **Skendros P**. Angiotensin II triggers release of neutrophil extracellular traps, linking thromboinflammation with essential hypertension. *JCI Insight.* 2021 Sep 22;6(18):e148668.
- Synolaki E, Papadopoulos V, Divolis G,....., **Skendros P\***, Sideras P\*. The Activin/Follistatin Axis Is Severely Deregulated in COVID-19 and Independently Associated With In-Hospital Mortality. *J Infect Dis.* 2021 May 20;223(9):1544-1554. doi: 10.1093/infdis/jiab108. PMID: 33625513; \*co-supervision
- **Skendros P**, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. *J Clin Invest.* 2020 Nov 2;130(11):6151-6157.
- Angelidou I, Chrysanthopoulou A, Mitsios A,....., **Skendros P**. REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1 $\beta$  Inflammatory Response in Active Ulcerative Colitis. *J Immunol.* 2018 Jun 15;200(12):3950-3961.
- **Skendros P**, Chrysanthopoulou A, Rousset F, et al. Regulated in development and DNA damage responses 1 (REDD1) links stress with IL-1 $\beta$ -mediated familial Mediterranean fever attack through autophagy-driven neutrophil extracellular traps. *J Allergy Clin Immunol.* 2017 Nov;140(5):1378-1387.e13.
- Apostolidou E\*, **Skendros P\***, Kambas K, et al. Neutrophil extracellular traps regulate IL-1 $\beta$ -mediated inflammation in familial Mediterranean fever. *Ann Rheum Dis.* 2016 Jan;75(1):269-77. \*First co-authors

### **Funded research projects (last 5 years):**

- InTechThrace - ATHERONET. Study of neutrophil/platelet interaction to identify and validate new inflammatory biomarkers in atherosclerosis and cardiovascular risk stratification. Pilot study in the framework of the InTechThrace Regional Excellence program: Integration of technologies for biomedical research: multilevel biomarker analysis in Thrace. Operational Program "Entrepreneurship Competitiveness and Innovation" (EPANEK), which is co-financed by the European Regional Development Fund (ERDF) and national resources (ESRA 2014-2020). 2021-2023. Coordinator and EY InTechThrace M. Koffa, Coordinator for ATHERONET: P. Skendros
  
- CYTONET. Development and prototyping of an innovative method for rapid differential diagnosis and rational selection of personalized treatment in inflammatory diseases based on disease-specific expression of cytokines during NETosis of peripheral blood neutrophils. EYDE-ETAK Research & Innovation Programme. 2019-2023. Coordinator and PI of the consortium: P. Skendros.
  
- BRIDGING. Novel targets for diagnostic stratification and epidemiologic surveillance of human brucellosis: host-guided molecular study in an endemic area at the crossroad between Asia and Europe. BMBF/GSRT German-Greek Bilateral Research & Innovation Programme 2018-2021: Coordinator of the consortium & PI for the Greek partners: P. Skendros. <http://www.bridgingproject.eu/>
  
- NEUTROVED. Vedolizumab and innate immunity: Effect of treatment with vedolizumab on neutrophils of patients with ulcerative colitis. Investigator Initiated Sponsored Research (IISR) protocol. Takeda. PI: G. Kouklakis, Co-PI P. Skendros, IISR-2019-103010, 2020-2023.